Treatment With BIBW 2992, Irreversible Inhibitor of EGFR and HER-2 in Non Small Cell Lung Cancer in Advanced Stage, Which Have Progressed to Chemotherapy. Analysis of Mutations in EGFR and Number of Copies of HER-2
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 07 Mar 2017
At a glance
- Drugs Afatinib (Primary)
- Indications Non-small cell lung cancer
- Focus Pharmacogenomic; Therapeutic Use
- 07 Jun 2017 Biomarkers information updated
- 01 Mar 2017 Planned End Date changed from 1 Jun 2016 to 1 Jun 2017.
- 09 Sep 2015 Primary endpoint (Overall survival) has been met as per results presented at the 16th World Conference on Lung Cancer.